$NUVB

Citigroup initiated coverage on Nuvation Bio (NUVB) and Jazz Pharmaceuticals (JAZZ) with Buy ratings. NUVB received a $12 price target, citing strong sales of Ibtrozi and potential of safusidenib. JAZZ was given a $320 target, highlighting Ziihera's growth potential. Both stocks are seen as covered call opportunities.

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

Nuvation Bio (NUVB) shares rose premarket after the FDA approved a label update for its cancer therapy Ibtrozi, including new mid-stage trial data. The update followed a supplemental New Drug Application approval.

Nuvation Bio (NUVB) announced FDA approval of its supplemental New Drug Application for IBTROZI (taletrectinib), updating the label to reflect a median duration of response of 49.7 months in TKI-naïve advanced ROS1-positive NSCLC patients. The approval, four months ahead of schedule, includes no new safety signals. IBTROZI is already approved in the U.S., Japan, and China, with regulatory reviews ongoing in Europe and the UK.

Jim Cramer called Nuvation Bio (NUVB) a 'pure spec' on CNBC's Mad Money, warning of high risk due to its reliance on pipeline drugs. The stock surged after FDA granted Fast Track status to its brain cancer drug, Safusidenib, and its lung cancer drug, IBTROZI, became the top prescribed treatment. Analysts expect 113% upside, but Cramer cautions about trial risks. NUVB is expected to post a net loss for 2026.

JPMorgan initiated coverage of Nuvation Bio (NUVB) with an Overweight rating and a $13 price target, implying 100% upside. The bank cited strong sales of IBTROZI, a lung cancer drug launched in 2026, and potential from safusidenib, an experimental brain tumor drug. Nuvation reported Q2 2026 revenue of $31.7M, beating estimates, but still operating at a loss. The stock has fallen 18% YTD but gained 8% in the past five days.

Nuvation Bio (NUVB) reported that its CSO, Gary Hattersley, exercised options for 100,000 shares at $1.87 each and sold them at $7.0924 per share under a 10b5-1 plan. The sale generated approximately $709K in gross proceeds, with a pre-tax spread of $522K. Hattersley retains 400,000 stock options, vesting over time until 2034.

Hattersley Gary (CHIEF SCIENTIFIC OFFICER) sold 100,000 shares of Nuvation Bio Inc. (NUVB) at $7.09 ($0.71M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Nuvation Bio (NUVB) stock rose 2.8% to $7.02 after the FDA granted Fast Track Designation to safusidenib, its therapy for IDH1-mutant glioma, citing Phase 2 study data. Cantor Fitzgerald initiated coverage with an Overweight rating and $12 price target, projecting peak sales of $965M for IBTROZI and $1.9B for safusidenib. The broader market also showed gains.

Analysts initiated coverage on five companies. Baird rated Hubbell (HUBB) Outperform with a $550 target. BMO rated Nvidia (NVDA) Outperform with a $340 target. Needham rated Faeth Therapeutics (FTH) Buy with a $56 target. Citizens rated Builders FirstSource (BLDR) Market Perform. Cantor Fitzgerald rated Nuvation Bio (NUVB) Overweight.